Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · Real-Time Price · USD
2.187
-0.073 (-3.24%)
Jan 8, 2025, 12:34 PM EST - Market open
-3.24%
Market Cap 41.24M
Revenue (ttm) n/a
Net Income (ttm) -14.40M
Shares Out 18.86M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 67,995
Open 2.230
Previous Close 2.260
Day's Range 2.160 - 2.339
52-Week Range 0.460 - 2.550
Beta 0.43
Analysts Strong Buy
Price Target 7.50 (+242.97%)
Earnings Date Nov 14, 2024

About CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 20
Stock Exchange NASDAQ
Ticker Symbol CMMB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CMMB stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 242.97% from the latest price.

Price Target
$7.5
(242.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

—Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with “Key, Near-Term, Potentially Stock-Moving Catalysts”— TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- ...

5 weeks ago - GlobeNewsWire

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Oral presentation at AASLD highlights broad clinical activity of Chemomab's CM-101 across multiple biomarkers and its disease-modifying potential in PSC

7 weeks ago - GlobeNewsWire

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25.

5 months ago - GlobeNewsWire

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics f...

5 months ago - GlobeNewsWire

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026

5 months ago - GlobeNewsWire

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

5 months ago - GlobeNewsWire

Chemomab Therapeutics Announces $10 Million Private Placement

Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.

5 months ago - GlobeNewsWire

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints

5 months ago - GlobeNewsWire

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —Ne...

7 months ago - GlobeNewsWire

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

8 months ago - GlobeNewsWire

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrol...

8 months ago - GlobeNewsWire

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

8 months ago - GlobeNewsWire

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator...

8 months ago - GlobeNewsWire

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflamma...

9 months ago - GlobeNewsWire

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis

9 months ago - GlobeNewsWire

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.

10 months ago - GlobeNewsWire

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.

10 months ago - GlobeNewsWire

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025 ─ ─Cash Runway Extended through End o...

10 months ago - PRNewsWire

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

TEL AVIV, Israel , March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory ...

11 months ago - PRNewsWire

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

—CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024— — New CM-101 Patents Granted by Brazil and Isr...

11 months ago - PRNewsWire

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

TEL AVIV, Israel , Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

11 months ago - PRNewsWire

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

TEL AVIV, Israel , Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative ther...

1 year ago - PRNewsWire

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the P...

1 year ago - PRNewsWire

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

—Expected Topline Data Readout Accelerated to Midyear 2024 Following Early Completion of Patient Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial— —CM-101's Unique Dual Anti-Fib...

1 year ago - PRNewsWire

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension -- -- Study Reveals that CCL24 Ac...

1 year ago - PRNewsWire